[Form 4] MiNK Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

MiNK Therapeutics director Ulf Wiinberg received a grant of stock options on 09/09/2025 allowing purchase of 3,225 shares of common stock at an exercise price of $15.36 per share. The Form 4 shows the options were acquired (transaction code A) and the reporting person beneficially owns 3,225 shares following the transaction. The option term includes an expiration date shown as 09/09/2035 on the filing, and the filing discloses the option vests in full on the one‑year anniversary of the grant if the director continues to serve on the board through that date. The reporting person is identified as a director and the Form 4 was signed by an attorney‑in‑fact.

Positive

• Director equity alignment: Grant vests in full after one year, aligning the director's compensation with shareholder outcomes over time.
• Clear disclosure: The Form 4 lists transaction date, amount (3,225 options), exercise price ($15.36) and an expiration date (09/09/2035), providing transparent reporting of the transaction.

Negative

• None.

Insights

Financial Analyst

TL;DR: Routine director option grant; modestly aligns interests without material immediate financial impact.

The filing documents a single option grant to a director for 3,225 shares at a $15.36 exercise price, with a ten‑year contractual horizon reflected by a 09/09/2035 expiration date. Vesting is simple and time‑based (full vest at one year), which indicates retention-focused alignment rather than performance linkage. The grant size relative to company cap is not provided, so materiality to EPS or share count cannot be assessed from this filing alone.

Corporate Governance Expert

TL;DR: Standard governance practice—time‑based equity awarded to a director; disclosure is complete for the transaction itself.

The Form 4 properly reports the director status, transaction date, amount, exercise price, and vesting condition. The one‑year cliff vesting is typical for director retention awards. The filing does not show any linked performance conditions or related‑party arrangements beyond the director relationship; no governance red flags are evident in the disclosed information.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WIINBERG ULF

(Last) (First) (Middle)

149 FIFTH AVENUE, SUITE 500

(Street)

NEW YORK NY 10010

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MiNK Therapeutics, Inc. [ INKT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$15.36	09/09/2025		A		3,225		(1)	09/09/2035	Common Stock	3,225	$0	3,225	D

Explanation of Responses:

1. The option vests in full on the one-year anniversary of the date of grant, provided that the Reporting Person continues to serve on the Issuer's Board of Directors through such date.

	By: /s/ Christine Klaskin, Attorney-in-Fact	09/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who filed the Form 4 for MiNK Therapeutics (INKT)?

The reporting person is Ulf Wiinberg, identified as a director; the form was signed by attorney‑in‑fact Christine Klaskin on 09/11/2025.

What security and amount were reported on the Form 4 for INKT?

A grant of stock options to purchase 3,225 shares of common stock was reported.

What is the exercise price and term of the options reported on the INKT Form 4?

The exercise (conversion) price is $15.36 per share and the filing shows an expiration date of 09/09/2035.

When do the options vest according to the Form 4 for INKT?

The filing states the option vests in full on the one‑year anniversary of the grant date, conditional on continued board service.

Does the Form 4 indicate whether the transaction was a purchase or a grant?

The transaction code is A (acquisition), indicating the reporting person acquired the option on 09/09/2025.